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Background {#sec1}
==========

Entry of corona viruses (CoVs) into target host cells occurs with the help of spike (S) transmembrane glycoprotein which projects out from the surface of virus in the form of homo-trimers ([@bib1]). This protein (S) consists of a small intracellular tail, a trans-membrane anchor, and a large sized ectodomain composed of receptor-binding S1 subunit, and cell membrane-fusing S2 subunit ([@bib2]). S1 subunit initiates the process of viral entry via attaching with cell receptor while S2 subunit facilities the viral fusion with cell membrane ([@bib3]). The protein S is cleaved at S2' by proteases present in host cell ([@bib4]) leading to the activation of this protein for fusion with cell membrane through a spectrum of permanent conformational modifications ([@bib5],[@bib6]). Thus, viral entry is a complicated process depending on combined event of protein S- receptor binding and proteolytic protein S processing ([@bib3]).

Hypothesis {#sec2}
==========

Though protein S of SARS-CoV-2 shows merely 75% similarity with the S protein of SARS-CoV as depicted from sequence analysis ([@bib7],[@bib8]) but S protein receptor-binding motif (RBM) analysis shows that majority of amino acid residues vital for receptor binding are conserved between SARS-CoV and, SARS-CoV-2, signifying that these two strains of CoVs make use of the same receptor for entering into host cell ([@bib9]) which is Angiotensin converting enzyme 2 (ACE2) ([@bib8],[@bib10],[@bib11]). Since the spike (S) protein is the viral component that with the cleaving action of host proteases facilitates the CoV-2 entry into the host cellular cytoplasm, thus a hypothesis is arises "could the blocking of viral S1 subunit and inhibiting of proteases simultaneously with host-friendly inhibitors make the CoV-2 handicapped and prevent its complete entry into target cells". [Figure 1](#fig1){ref-type="fig"} shows the mechanism of CoV-2 entry into target cell. The theoretical model for inhibiting receptor-binding S1and S′-proteases interplay is depicted in [Figure 2](#fig2){ref-type="fig"} . We suggest that S1 subunit and host proteases as potential therapeutic avenues for the treatment of COVID-19.Figure 1Mechanism of SARS-CoV-2 entry into target cell.Figure 2Blocking of S1 Subunit and protease inhibition prevents the SARS-CoV-2 entry into target cell.
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